Holocene Advisors
EIDX

Holocene Advisors’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

Holocene Advisors’s Portfolio EIDX Stock Details EIDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-167,581
Closed -$9.62M – 876
2019
Q4 		$9.62M Buy
+167,581
New +$8.3M 0.09% 154

Other funds holding EIDX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Holocene Advisors's EIDX Position: Q1 2020 in Review

Holocene Advisors sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q1 2020, closing a stake of 167,581 shares — an estimated $9.62M sold.

Holocene Advisors first reported a position in EIDX in Q4 2019 and held it in 1 quarter. The position peaked at $9.62M in Q4 2019. 89 funds tracked by Wall St. Rank hold EIDX as of Q1 2020.

  • Holocene Advisors reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
  • Holocene Advisors sold 167,581 Eidos Therapeutics, Inc. Common Stock shares in Q1 2020, an estimated $9.62M.
  • Holocene Advisors first reported a position in Eidos Therapeutics, Inc. Common Stock in Q4 2019 and held it in 1 quarter.
  • Holocene Advisors's Eidos Therapeutics, Inc. Common Stock position peaked at $9.62M in Q4 2019.
  • 89 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q1 2020.

Based on Holocene Advisors's 13F filing for Q1 2020, filed 15 May 2020.